Breaking News
September 25, 2018 - New program to reduce harmful stress effectively improves mood in cancer patients
September 24, 2018 - Florence’s Lingering Threat: Mold – Drugs.com MedNews
September 24, 2018 - For professional baseball players, faster hand-eye coordination linked to batting performance
September 24, 2018 - Bill for later school start times is defeated, but Stanford sleep specialist isn’t
September 24, 2018 - For Heart Failure Patients, Mitral Valve Procedure Improved Outcomes
September 24, 2018 - Successful recovery from addiction means more than achieving abstinence
September 24, 2018 - New nanoplatform technology may reverse drug-resistance in renal cell carcinoma
September 24, 2018 - October 1918 marks the centenary of Spanish Flu that claimed more lives than World War I
September 24, 2018 - LGBT community reports more number of poor mental health days than general population
September 24, 2018 - New research suggests power of zebrafish as tool for cancer drug discovery
September 24, 2018 - New study finds height as possible risk factor for developing varicose veins
September 24, 2018 - Researchers compare weight loss results of online and in-person diabetes prevention program
September 24, 2018 - New HER2 PET Study Uses Affibody’s ABY-025 Tracer to Individualize Breast Cancer Treatment
September 24, 2018 - Drug combination offers more effective care for patients suffering miscarriage
September 24, 2018 - Tallness linked to varicose veins, Stanford study says
September 24, 2018 - For Heart Failure Patients, Mitral Valve Procedure Improved Outcomes
September 24, 2018 - Ecstasy drug makes octopuses more social
September 24, 2018 - Immediate compression therapy could cut risk of complications after deep-vein thrombosis
September 24, 2018 - Transcatheter mitral valve repair reduces mortality for patients with mitral regurgitation
September 24, 2018 - First intracranial aneurysm patients treated with BRAVO Flow Diverter after CE mark approval
September 24, 2018 - ‘Physicians of the mouth’? Dentists absorb the medical billing drill
September 24, 2018 - People more likely to believe those with confident tone of voice than with accent
September 24, 2018 - Harmony Biosciences Presents 5-Year Data On Pitolisant At International Narcolepsy Symposium
September 24, 2018 - Blood test may identify gestational diabetes risk in first trimester
September 24, 2018 - Height may be risk factor for varicose veins | News Center
September 24, 2018 - King’s commemorates opening of new NMR facility with one-day symposium
September 24, 2018 - Eisai receives approval for partial label change of DC Bead device for transcatheter arterial embolization
September 24, 2018 - High-resolution genomic map gives scientists unprecedented view of brain development
September 24, 2018 - Alexion announces positive results from Phase 3 PREVENT study of Soliris in patients with NMOSD
September 24, 2018 - First evaluation of benefits, harms of Alzheimer’s screening for family members of older adults
September 24, 2018 - Ancora Heart announces positive data of study evaluating AccuCinch Ventricular Repair System
September 24, 2018 - Children of mothers using cannabis may start using it at an earlier age, finds study
September 24, 2018 - Gilead Sciences plans to launch authorized generic versions of Epclusa and Harvoni in the US
September 24, 2018 - Most patients who underwent transcatheter valve replacement experience prosthesis-patient mismatch
September 24, 2018 - Lumos acquires license for LUM-201 drug that promotes secretion of growth hormone
September 24, 2018 - New study provides basis for Air Canada to change its facial hair policy for aircrew
September 24, 2018 - Infant walkers lead to thousands of emergency visits for babies
September 24, 2018 - Genes predicting person’s height may provide clues about causes of varicose veins
September 24, 2018 - EPA Plan Will Maintain Carbon Emissions From Power Plants
September 24, 2018 - Characterizing pig hippocampus could improve translational neuroscience
September 24, 2018 - Element3 Health reports social and mental engagement play key role in overall health
September 24, 2018 - Paralympic medalists support Fight for Sight’s unique virtual event
September 24, 2018 - ADCETRIS drug receives approval in Japan as frontline treatment option for Hodgkin lymphoma
September 24, 2018 - Public awareness of urological conditions found to be alarmingly low across Europe
September 24, 2018 - Fitter Folks Suffer Milder Strokes: Study
September 24, 2018 - Novel botulinum toxin compound relieves chronic pain
September 24, 2018 - CHMP recommends approval of Gilenya for treatment of multiple sclerosis in children, adolescents
September 24, 2018 - National Friendly’s private medical insurance is a hit with women living in the South East
September 24, 2018 - Academics receive prestigious awards for achievements in blood pressure research
September 24, 2018 - Obese pregnant women can restrict weight gain safely with proper nutrition guidance
September 24, 2018 - CHMP adopts positive opinion of Takeda’s ALUNBRIG for treatment of ALK+ non-small cell lung cancer
September 24, 2018 - China NMPA approves LENVIMA for treatment of unresectable hepatocellular carcinoma
September 24, 2018 - A new approach for finding Alzheimer’s treatments
September 24, 2018 - USC research uncovers previously unknown genetic risk factor for dementia
September 24, 2018 - Study examining mental health among students finds significant disparities in treatment across race
September 24, 2018 - Breakthrough discovery paves way for future test to identify drowsy drivers
September 24, 2018 - Transcatheter mitral-valve repair in patients with heart failure
September 24, 2018 - Study opens new avenues for treatment of Laing distal myopathy
September 24, 2018 - Stroke Facts | cdc.gov
September 24, 2018 - Sarcolipin tricks muscle cells into using more energy, burning fat
September 24, 2018 - Enrollment in opioid controlled substance agreement reduces primary care visits
September 24, 2018 - UTA researchers patent new smart seat cushion technology that helps prevent painful ulcers
September 24, 2018 - Second HPV-Related Primary Cancers Common in Survivors
September 24, 2018 - How a virus destabilizes the genome
September 24, 2018 - Old letters provide insight into Spanish flu pandemic horror
September 23, 2018 - Smart textile-based soft robotic exosuit helps wearers save energy and traverse difficult terrain
September 23, 2018 - New research hub to drive radical change in development and manufacturing of vaccines
September 23, 2018 - AHA: For Hispanics, Neighborhood May Be Key Factor in Heart Disease Risk
September 23, 2018 - Excessive airway nerves tied to more severe asthma symptoms, study finds
September 23, 2018 - Study highlights need to remain vigilant in maintaining key infection control processes
September 23, 2018 - Novel therapeutic strategy for blood vessel related disorders, such as cancer and retinopathy
September 23, 2018 - New naturally occurring antibiotic found effective against Mycobacterium tuberculosis
September 23, 2018 - First-in-human phase 0 study shows clinically-relevant activity of new drug in glioblastoma
September 23, 2018 - Removing tobacco product display from shops reduced number of children buying cigarettes
September 23, 2018 - Random fraction of specialized immune cells leads the charge in battling invaders
September 23, 2018 - Few minutes of sprinting exercise may be as effective as longer exercise sessions
September 23, 2018 - Researchers use neutrons to make first direct observations of water in lipid bilayers
September 23, 2018 - Researchers demonstrate pre-clinical success for universal flu vaccine in new paper
September 23, 2018 - Study reveals surprising gaps in some HIV medical providers’ knowledge of ACA
September 23, 2018 - Oxehealth secures European medical device accreditation for vital signs measurement software
Gene Therapy Offers Hope for Inherited Retinal Disorder

Gene Therapy Offers Hope for Inherited Retinal Disorder

image_pdfDownload PDFimage_print

Action Points

  • Note that this study was published as an abstract and presented at a conference. These data and conclusions should be considered to be preliminary until published in a peer-reviewed journal.
  • Patients with inherited retinal disease due to biallelic mutation in the RPE65 gene had sustained functional vision improvement when treated with voretigene neparvovec (Luxturna), according to a phase III study in 29 patients.
  • Note that RPE65 is an isomerohydrolase enzyme (expressed in the retinal pigment epithelium) that converts vitamin A from an inactive to an active form, and is responsible for rod and cone functioning.

NEW ORLEANS — Gene augmentation by voretigene neparvovec (Luxturna) improves functional vision in patients with biallelic mutation in the RPE65 gene, a mutation that results in inherited retinal disease, researchers reported here.

Twenty seven of 29 (93%) of patients with Leber congenital amaurosis (LCA) who were treated with the investigational gene therapy had their vision improved to the degree that they could navigate a maze in low to moderate light. They also demonstrated improvement in light sensitivity and peripheral vision, according to Stephen R. Russell, MD, of the University of Iowa in Iowa City, and colleagues.

The improvement was maintained to 3 years, according to updated data from a phase III study presented at the American Academy of Ophthalmology (AAO) meeting.

In October, an FDA advisory committee unanimously recommended approval of the gene treatment for patients with vision loss due to confirmed biallelic RPEmutation-associated retinal dystrophy. The FDA is expected to render a decision no later than January 2018.

“So far, we have followed patients for up to 4 years, and have not seen any significant drop-off,” Russell said at an AAO, press briefing. “We will be observing these patients up to 15 years by FDA protocol.”

RPE65 is an isomerohydrolase enzyme expressed in the retinal pigment epithelium; this enzyme converts vitamin A from an inactive to an active form. The expression of the RPE65 gene is responsible for rod and cone functioning. Autosomal-recessive mutations in the RPE65 gene result in difficulty in navigating unfamiliar environments, night blindness, loss of visual acuity, and a progressive loss of the visual field.

The effect of noretigene neparvovec was studied in a 1-year open-label, randomized, controlled study period, after which patients in the control group could cross over to active treatment. The treatment was delivered bilaterally, 6 to 18 days apart.

The 31 patients, ages 4 to 44 years at the time of treatment, were randomized in a 2:1 ratio to treatment (n=21) or control (n=10).

The primary endpoint was the change in bilateral performance in the multi-luminance mobility test (MLMT), an endpoint designed specifically for LCA, at 1 year. The MLMT measures functional performance through navigation of a mobility course in which participants follow arrows and avoid obstacles. The test was conducted at various light levels, ranging from 1 to 400 lux. The course navigation was captured on video and graded for accuracy and time.

At 1 year, per the mean change in the bilateral MLMT score differed by 1.6 in favor of the active treatment (95% CI 0.72-2.41, P=0.0013). Those who received gene therapy also showed a marked improvement compared with controls in full-field light sensitivity (FST) threshold testing averaged over both eyes (P=0.0004) and MLMT change score for the first injected eye (P=0.0005).

However, the change in visual acuity averaged over both eyes was not significantly different between intervention and control patients (P=0.17).

The mean bilateral MLMT score change at 3 years for 20 patients originally randomized to gene augmentation was 1.8. In nine patients who crossed over, the mean bilateral score change was 2.1 relative to injection baseline after year 1.

Similarly, the mean change from baseline in white light FST was 2.04 at year 3 in 19 participants who received noretigene neparvovec. This same score improved by 2.69 at year 2 in the nine patients who crossed over.

The change in mean visual acuity score was consistent through year 2 for the crossover population and through year 3 in the population originally randomized to noretigene neparvovec. “We have a very small population, so there’s a lot of variability,” Russell stated.

“There were no serious ocular surgery concerns,” he said. “The complications that we saw were largely related to the procedure of placing the subretinal gene therapy as opposed to agent-related reactions.”

Ten patients (17%) had cataracts and three (10%) had intraoperative retinal tears that were treated at the time of gene therapy. Three patients (10%) had retinal deposits.

Irene Maumenee, MD, of the Ocular Genetics Laboratory at the University of Illinois in Chicago, said the results represent the beginning of a treatment wave of genetic eye disease, with further improvements down the road. She cautioned that it may be premature to treat without a full understanding of the variation in disease that occurs with mutation in the same gene.

“Has there ever been any treatment where the dosage was right from the beginning?” she stated. “Probably not. So if this is the first wave of treatment that would be 100% correct, [that ] is … maybe presumptuous. There are so many problems to overcome from the beginning.” Maumenee was not involved in the study.

Russell disclosed a relevant relationship with Spark Therapeutics.

1969-12-31T19:00:00-0500

last updated

Tagged with:

About author

Related Articles